| | | Costly amendments are often avoidable a Tufts study shows. See how some CROs are helping sponsors prevent unnecessary changes with stronger protocol design, stakeholder input, and smarter amendment bundling.
Read the Article for Free. +(002)+140w+(3).png)
|
|
Today’s Big News Apr 4, 2025 |
| Tuesday, April 8, 2025 | 1pm ET / 10am PT Learn how AI-powered digital phenotyping and real-world data (RWD) help identify overlooked patient populations, bridge gaps between clinical guidelines and real-world treatment, and refine commercial strategies. Join experts to discover how AI-driven insights can optimize market positioning and ensure therapies reach the right patients. Register now! 
|
|
| | By Darren Incorvaia Sangamo Therapeutics has secured a licensing deal with Eli Lilly that helps extend the cash-strapped company’s runway. Lilly will pay Sangamo $18 million upfront for the rights to use Sangamo’s neurotropic adeno-associated virus capsid to develop a genomic treatment for a central nervous system disease, Sangamo announced on April 3. |
|
|
|
| By Darren Incorvaia Relay Therapeutics has laid off about 70 employees, the biotech's third round of cuts in less than a year. |
| By Nick Paul Taylor Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at Oncodesign Precision Medicine (OPM). The loss of a shot at a milestone prompted OPM to lay off staff and halve the salaries of two top executives. |
| Sponsored by Allucent Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how sponsors can align with FDA expectations and implement more precise dose-finding strategies. Watch the full interview with Alex MacDonald now! |
| Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
| By Noah Tong,Dave Muoio,Emma Beavins After sending out termination notices to 10,000 more HHS workers, some are being told their positions shouldn't have been eliminated. |
| By Darren Incorvaia,Zoey Becker As the Department of Health and Human Services grapples with the fallout of mass layoffs directed by Secretary Robert F. Kennedy Jr., top leadership at several agencies is on the outs. |
| By Gabrielle Masson After a drawn-out acquisition that closed in 2023, U.K. biotech F-star Therapeutics is charting its own path as a private, independent company. |
| By Nick Paul Taylor Apollomics has tagged out of its partnership with TYG Oncology, terminating an immuno-oncology pact as part of a push to cut costs and keep going into 2026. |
| By Gabrielle Masson The California biotech will use the cash infusion to support its pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead candidate that takes aim at a common form of epilepsy. |
| By Kevin Dunleavy President Donald Trump’s announcement on Wednesday that pharmaceuticals imported to the U.S. would be exempt from tariff payments brought a sigh of relief from major drugmakers. But at the same time, industry leaders are bracing for the news that they think is inevitable given Trump’s declaration in February to impose “25% or higher” levies on imported drugs. |
| By Fraiser Kansteiner Massive cuts at the FDA have hit staff tied to drug reviews and user fees, putting future approvals in jeopardy, according to multiple reports. |
| By Ayla Ellison,Darren Incorvaia,Gabrielle Masson This week on "The Top Line," we dive into our special report ranking the top pharma R&D budgets for 2024. |
| By Kevin Dunleavy In response to a request from the European Medicines Agency following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in Europe of their Duchenne muscular dystrophy gene therapy Elevidys. |
| By Anastassia Gliadkovskaya Fierce Healthcare talked to a dozen experts about what key changes the U.S. has gone through since COVID-19 became a pandemic. Here are their takeaways. |
| By Angus Liu Several pharma CEOs met with Chinese President Xi Jinping in Beijing. Donald Trump's reciprocal tariffs have mostly spared pharmaceuticals. BioNTech's PD-L1xVEGF bispecific antibody, bought from China's Biotheus, showed promise in small cell lung cancer. And more. |
| Fierce podcasts Don’t miss an episode |
| | This week on "The Top Line," we dive into our special report ranking the top pharma R&D budgets for 2024. |
|
|---|
|
|
| Wednesday, April 9, 2025 | 11am ET / 8am PT Copay programs are designed to make treatments more affordable, but too often, patients don’t know they exist or how to use them. That means financial assistance goes unused, medications go unfilled, and patients face unnecessary barriers to starting and staying on treatment. Join us to learn how to move beyond outdated, manual copay distribution methods. Register now. |
|
| Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
| Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| | Accepting Nominations Now |
|
| | Accepting Nominations Now |
|
|
| | |
|
